JPRN-jRCT2080221937未知3 期
Phase III Clinical Study of Ro200-5450po (Ibandronic acid) for Primary Osteoporosis
适应症
试验速览
- 阶段
- 3 期
- 入组人数
- 396
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 55age old 至 ot applicable（—）
- 性别
- All
入选标准
- •Primary osteoporosis
排除标准
- •Secondary osteoporosis
研究者
相似试验
未知
2 期
Phase II/III Clinical Study of R484iv (Ibandronic acid) for Primary OsteoporosisOsteoporosisJPRN-jRCT2080220364Chugai Pharmaceutical Co., Ltd. Taisho Pharmaceutical Co., Ltd.
已完成
2 期
A phase II/III clinical study of R442(Pegylated Interferon alfa-2a) for patients with chronic hepatitis B.chronic hepatitis BJPRN-UMIN000000692CHUGAI PHARMACEUTICAL CO.LTD.260
未知
1 期
Phase I of RG3502 in Combination With RG1273HER2 positive Breast CancerJPRN-jRCT2080221197Chugai Pharmaceutical Co., Ltd.6
未知
3 期
MK-0431/ONO-5435 Phase III Clinical Study - Long-term Treatment Study for Patients with Type 2 Diabetes MellitusType 2 Diabetes MellitusJPRN-jRCT2080220289ONO PHARMACEUTICAL CO.,LTD.
未知
3 期
A phase II/III clinical study of R442 (Pegylated Interferon alfa-2a) for patients with chronic hepatitis B.chronic hepatitis BJPRN-jRCT2080220384Chugai Pharmaceutical Co., Ltd.